Can two targeted drugs keep HER2 lung cancer from coming back?
Disease control
Not yet recruiting
Researchers are testing whether adding trastuzumab rezetecan, adebrelimab, or both after chemoradiotherapy can help people with unresectable stage III non-small cell lung cancer that has HER2 changes. The trial enrolls about 105 adults whose cancer has not worsened after definiti…
Phase 2 • Sponsor: Ming Chen • Aim: Disease control
Last updated Sep 25, 2026 00:00 UTC